Header Logo

Connection

Anthonet Koen to Antibodies, Viral

This is a "connection" page, showing publications Anthonet Koen has written about Antibodies, Viral.
Connection Strength

0,740
  1. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
    View in: PubMed
    Score: 0,158
  2. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. Vaccine. 2020 05 08; 38(22):3862-3868.
    View in: PubMed
    Score: 0,150
  3. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ. 2014 Apr 01; 92(4):238-45.
    View in: PubMed
    Score: 0,098
  4. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
    View in: PubMed
    Score: 0,050
  5. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
    View in: PubMed
    Score: 0,047
  6. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
    View in: PubMed
    Score: 0,045
  7. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine. 2021 09 15; 39(39):5513-5523.
    View in: PubMed
    Score: 0,041
  8. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,041
  9. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children. J Infect Dis. 2019 09 26; 220(9):1529-1538.
    View in: PubMed
    Score: 0,036
  10. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017 08; 17(8):843-853.
    View in: PubMed
    Score: 0,031
  11. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,024
  12. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.